Biolevate Raises €30M Series A for Auditable Life-Sciences AI Workflows

Biolevate Raises €30M Series A for Auditable Life-Sciences AI Workflows

Paris-founded Biolevate has raised a €30 million Series A co-led by RAISE France and Orange Ventures, with participation from MSD Global Health Innovation Fund, Station F and existing investor EQT Ventures. The company is opening a Boston office as it expands an enterprise agentic AI platform for scientific and regulatory work across research, clinical trials, health technology assessments, regulatory dossiers, drug discovery and development. Biolevate says the platform grounds outputs in source evidence and preserves human oversight for regulated deployments.

The financing is notable because Biolevate is selling automation into workflows where traceability matters as much as model capability. Its initial focus was regulatory approval work, but the product now spans multiple life-sciences functions; that broader scope positions it against the operational friction that slows evidence synthesis, regulatory intelligence and compliance. Biolevate says its platform can run up to 100,000 agents concurrently and has delivered a sixteenfold acceleration in systematic literature reviews and research synthesis, alongside an 80% efficiency gain in regulatory intelligence and compliance; those are company-reported figures.

For builders, the implication is that regulated life-sciences AI needs a workflow design centered on evidence, review and accountability rather than autonomous output alone. For investors, Biolevate's expansion from a narrowly defined regulatory use case toward a wider scientific-workflow platform will make enterprise deployment depth, repeatable governance and customer conversion more meaningful indicators than agent-count claims. The company says it serves more than a dozen enterprise customers, has doubled headcount in the past year, and plans to double it again.

#LifeSciencesAI #HealthcareAI #AgenticAI #RegulatoryTechnology #SeriesA